Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary
3.1. Market Snippet by Type
3.2. Market snippet by Therapy
3.3. Market snippet by Route of Administration
3.4. Market Snippet by End User
3.5. Market Snippet by Region

4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing research and development for the treatment of cancer will drive the market growth
4.1.1.2. The prevalence of achalasia is expected to drive growth of the esophageal cancer market growth
4.1.2. Restraints:
4.1.2.1. Side Effects associated with Certain Medications Coupled with High Cost of Cancer treatment
4.1.3. Opportunity
4.1.4. Impact Analysis

5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Unmet Needs

6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
7.3. Market Attractiveness Index, By Type Segment
7.3.1. Adenocarcinomas*
7.3.1.1. Introduction
7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3.1.3. Nucleoside Reverse transcriptase inhibitors (NRTIs)
7.3.2. Astrointestinal Stromal Tumors
7.3.3. Carcinoid Tumors
7.3.4. Squamous Cell Carcinoma
7.3.5. Other

8. By Therapy
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
8.1.2. Market Attractiveness Index, By Therapy
8.2. Targeted Therapy*
8.2.1. Introduction
8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3. Immunotherapy
8.4. Chemotherapy

9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
9.3. Parenteral
9.4. Others

10. By End User
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
10.1.2. Market Attractiveness Index, By End User Segment
10.2. Hospitals *
10.2.1. Introduction
10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
10.3. Clinics
10.4. Ambulatory Surgical Centers

11. By Region
11.1. Introduction
11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
11.3. Market Attractiveness Index, By Region
11.4. North America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. U.S.
11.4.7.2. Canada
11.4.7.3. Mexico
11.5. Europe
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Distribution Channel
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. Germany
11.5.7.2. U.K.
11.5.7.3. France
11.5.7.4. Italy
11.5.7.5. Spain
11.5.7.6. Rest of Europe
11.6. South America
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.6.7.1. Brazil
11.6.7.2. Argentina
11.6.7.3. Rest of South America
11.7. Asia Pacific
11.7.1. Introduction
11.7.2. Key Region-Specific Dynamics
11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.7.7.1. China
11.7.7.2. India
11.7.7.3. Japan
11.7.7.4. Australia
11.7.7.5. Rest of Asia Pacific
11.8. Middle East and Africa
11.8.1. Introduction
11.8.2. Key Region-Specific Dynamics
11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles
13.1. Amgen Inc. *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Eli Lilly and Company
13.3. Hoffmann-La Roche
13.4. Bristol-Myers Squibb Company
13.5. Boehringer Ingelheim GmbH
13.6. GlaxoSmithKline Plc.
13.7. Novartis AG
13.8. Johnson & Johnson
13.9. Gilead Sciences
13.10. Genentech Inc.(*LIST NOT EXHAUSTIVE)

14. Premium Insights

15. DataM Intelligence
15.1. Appendix
15.2. About Us and Services
15.3. Contact Us